Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder

International Journal of Urology

Volumn 10, Issue 1, 2003, Pages 19-24

  Hara, Isao ^a   Miyake, Hideaki ^a   Takechi, Yoshizumi ^a   Eto, Hiroshi ^a   Gotoh, Akinobu ^a   Fujisawa, Masato ^a   Okada, Hiroshi ^a   Arakawa, Soichi ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Grade 3; Instillation of BCG; Progression; Recurrence; Superficial bladder cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; MITOMYCIN;

ADULT; AGE; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER TUMOR; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG INSTILLATION; FEMALE; FOLLOW UP; GENDER; HUMAN; MALE; MULTIVARIATE ANALYSIS; MUSCLE METASTASIS; PRIORITY JOURNAL; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0037289009     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.2003.00559.x     Document Type: Article

References (24)

1. Pham HT, Soloway MS. High-risk superficial bladder cancer: intravesical therapy for T1, G3 transitional cell carcinoma of the urinary bladder. Semin. Urol. Oncol. 1997; 15: 147-53.
2. Jakse G, Loidl W, Seeber G et al. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J. Urol. 1987; 137: 39-43.
3. Amling CL, Thrasher JB, Frazier HA et al. Radical cystectomy for stage Ta, Tis and T1 transitional cell carcinoma of the bladder. J. Urol. 1994; 151: 31-6.
4. Kakizoe T, Tobisu M, Mizutani T et al. An analysis by step sectioning of early invasive bladder cancer with special reference to G3, pT1 disease. Jpn. J. Cancer Res. 1992; 83: 1354-8.
5. Soloway M. The management of superficial bladder cancer. Cancer 1980; 45: 1856-65.
6. Sarosdy MF, Lamm DL. Long-term results of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J. Urol. 1989; 142: 719-22.
7. Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. N. Engl. J. Med. 1991; 325: 1205-9.
8. Gohji K, Nomi M, Okamoto M et al. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 1999; 53: 308-13.
9. Hurle R, Losa A, Manzetti A et al. Intravesical bacillus Calmette-Guérin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999; 54: 258-63.
10. Baniel J, Grauss D, Engelstein D et al. Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998; 52: 785-9.
11. Hurle R, Losa A, Ranieri A et al. Low dose Pasteur bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy. J. Urol. 1996; 156: 1602-5.
12. Schmitz-Drager BJ, Muller M. Intravesical treatment of bladder cancer: current problems and needs. Urol. Int. 1998; 61: 199-205.
13. Naito S, Kotoh S, Omoto T et al. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapermil versus doxorubicin alone. Cancer Chemother. Pharmacol. 1998; 42: 367-72.
14. Vicente J, Laguna MP, Duarte D et al. Carcinoma in situ as a prognostic factor for G3, PT1 bladder tumors. Br. J. Urol. 1991; 68: 380-2.
15. Anderson G, Johansson S, Nilsson S. The significance of lamina propria invasion on the prognosis of patients with bladder tumors. J. Urol. 1980; 124: 23-6.
16. England HR, Paris AM, Blandy JP. The correlation of T1 bladder tumour history with prognosis and follow-up requirements. Br. J. Urol. 1981; 53: 593-7.
17. Herr HW. Tumor progression and survival in patients with T1G3 bladder tumors: 15-year outcome. Br. J. Urol. 1997; 80: 762-5.
18. Pagano F, Bassi P, Milani C et al. A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: is it effective? J. Urol. 1991; 146: 32-5.
19. Herr HW, Wartinger DD, Fair WR et al. BCG therapy for superficial bladder cancer: a 10-year followup. J. Urol. 1992; 147: 1020-3.
20. Morales A, Nickel JC, Wilson JW. Dose-response of bacillus Calmette-Guérin in the treatment of superficial bladder cancer. J. Urol. 1992; 147: 1256-8.
21. Hudson MA, Ratliff TL, Gillen DP et al. Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: a prospective, randomized trial. J. Urol. 1987; 138: 295-8.
22. Malkowicz SB, Nichols P, Lieskovsky G et al. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J. Urol. 1990; 144: 641-5.
23. Stokle M, Alken P, Engelman U et al. Radical cystectomy - often too late? Eur. Urol. 1987; 13: 361-7.
24. Lebret T, Becette V, Barbagelatta M et al. Correlation between p53 over expression and response to bacillus Calmette-Guérin therapy in a high risk select population of patients with T1G3 bladder. J. Urol. 1998; 159: 788-91.